Bristol-Myers outlook still rocky
481445
Bristol-Myers Squibb's   much-criticized chief executive is now out of the picture, but  company earnings prospects remain bleak and the absence of a  permanent new leader could make the drugmaker prey to a  takeover, analysts said on Tuesday.
332186
The data from the housing sector continues to be ugly, but the stocks have been on fire.
164709
The company's stock has had a rough few months, but the business still looks strong.
82904
SHANGHAI -- Looking at the facts, the past year seems to have been disastrous for Worldbest Pharmaceutical.  First, there were reports of accounting irregularities and exaggerated profit. Half the managers were fired. Then, in the summer, six people died and at least 80 fell ill after receiving an antibiotic injection manufactured by a subsidiary. Most recently, the company warned investors that it was likely to report its third consecutive year of losses....
287168
Biomet operates in the appealing medical device industry, but current growth trends are giving investors a headache.
491379
The company has posted impressive growth, but the industry is struggling.
373228
This year has been tough for drug manufacturers and the advertising agencies that have been charged with marketing their products.
567816
This potential turnaround is still trying to turn.
581460
Genentech announces positive second-quarter results, but investors remain worried.
348955
The stock looks reasonably valued but some core businesses are struggling to grow.
282083
Weak market, poor performance of key titles but takeover talks still on
527411
Competition makes for a dreary outlook for the company.
268925
The British-Swedish drug company has a great quarter, but the future looks dimmer.
245874
Eli Lilly and Co.  said on Thursday it is on track to meet its 2006 growth forecast of 8 percent to 12 percent, but projected slower profit growth in 2007 though its revenues will grow at a faster pace next year.
591674
Bristol-Myers Squibb (nyse: BMY - news - people ) will report third-quarter earnings. Analysts surveyed by Thomson First Call expect the pharmaceutical maker to earn 39 cents per share compared with 47 cents a year ago.
636013
Pharma company weathered a tough year but should ride out its Vioxx troubles.
468841
Bristol-Myers Squibb's third-quarter profit was lower on amid intense competition for its products from rivals and generic drugs.